Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2021 · 10-Q
Revenue$17.31M$17.31M+22.1% vs Q3 2020 Net Income-$8.86M-$8.86MN/M vs Q3 2020 EPS Diluted-$0.13-$0.13N/M vs Q3 2020 Gross Profit$10,578,000+25.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,919,000N/M Margins · derivedGross margin61.1%+1.5 pt vs Q3 2020
Operating margin-51.1%−21.5 pt vs Q3 2020
Net margin-51.2%−21.4 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 3, 2021 · 34 d after period end